Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-panitumumab
- Development stage
- Phase 1
- Lead developer
- Vanderbilt-Ingram Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Peritumoral
01
Overview
111In-panitumumab is a radioimmunoconjugate composed of panitumumab (a fully human monoclonal antibody) labeled with the radioactive isotope indium-111. It targets the epidermal growth factor receptor (EGFR), which is overexpressed in many tumor types. This compound is designed for diagnostic imaging using SPECT/CT to visualize EGFR-expressing tumors and potentially identify sentinel lymph nodes in cancer patients. In preclinical studies, it has shown high tumor uptake, making it valuable for diagnostic applications.
- Other names
- 111In-DOTA-panitumumabpanitumumab-DOTA-111Inpanitumumab-DOTA111Inpanitumumab-DOTA 111In
02
Targets
Beyond the preview
Go deeper on 111In-panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-panitumumab.